Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – Attached to lymphokine – cytokine – or other secreted growth...
Reexamination Certificate
2011-07-19
2011-07-19
Huynh, Phuong (Department: 1644)
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
Attached to lymphokine, cytokine, or other secreted growth...
C424S001490, C424S001690, C424S009322, C424S085100, C424S085200, C424S085400, C424S134100, C424S183100, C424S193100, C435S069100, C530S324000, C530S325000, C530S351000, C530S385000, C530S387100, C530S391100, C530S397000
Reexamination Certificate
active
07981398
ABSTRACT:
The present invention concerns methods and compositions for forming PEGylated complexes of defined stoichiometry and structure. In preferred embodiments, the PEGylated complex is formed using dock-and-lock technology, by attaching a target agent to a DDD sequence and attaching a PEG moiety to an AD sequence and allowing the DDD sequence to bind to the AD sequence in a 2:1 stoichiometry, to form PEGylated complexes with two target agents and one PEG moiety. In alternative embodiments, the target agent may be attached to the AD sequence and the PEG to the DDD sequence to form PEGylated complexes with two PEG moieties and one target agent. In more preferred embodiments, the target agent may comprise any peptide or protein of physiologic or therapeutic activity. The PEGylated complexes exhibit a significantly slower rate of clearance when injected into a subject and are of use for treatment of a wide variety of diseases.
REFERENCES:
patent: 4046722 (1977-09-01), Rowland
patent: 4699784 (1987-10-01), Shih et al.
patent: 4868109 (1989-09-01), Lansdorp et al.
patent: 5770198 (1998-06-01), Coller et al.
patent: 6261537 (2001-07-01), Klaveness et al.
patent: 6306393 (2001-10-01), Goldenberg et al.
patent: 6524854 (2003-02-01), Monia et al.
patent: 7060506 (2006-06-01), Craig
patent: 7521056 (2009-04-01), Chang et al.
patent: 7527787 (2009-05-01), Chang et al.
patent: 7534866 (2009-05-01), Chang et al.
patent: 7550143 (2009-06-01), Chang et al.
patent: 7666400 (2010-02-01), Chang et al.
patent: 7858070 (2010-12-01), Chang et al.
patent: 7871622 (2011-01-01), Chang et al.
patent: 7901680 (2011-03-01), Chang et al.
patent: 2003/0198956 (2003-10-01), Makowski et al.
patent: 2003/0232420 (2003-12-01), Braun et al.
patent: 2004/0018587 (2004-01-01), Makowski et al.
patent: 2004/0126361 (2004-07-01), Saifer et al.
patent: 2005/0003403 (2005-01-01), Rossi et al.
patent: 2006/0210475 (2006-09-01), Goldenberg et al.
patent: 2006/0228300 (2006-10-01), Chang et al.
patent: 2007/0086942 (2007-04-01), Chang et al.
patent: 2007/0140966 (2007-06-01), Chang et al.
patent: 2007/0264265 (2007-11-01), Goldenberg et al.
patent: 2009/0060862 (2009-03-01), Chang et al.
patent: 2009/0111143 (2009-04-01), Goldenberg et al.
patent: 2009/0191225 (2009-07-01), Chang et al.
patent: 2009/0202433 (2009-08-01), Chang et al.
patent: 2009/0269277 (2009-10-01), Chang et al.
patent: 2009/0304580 (2009-12-01), Goldenberg et al.
patent: 2010/0068137 (2010-03-01), Chang et al.
patent: 2010/0189641 (2010-07-01), Chang et al.
patent: 2010/0189689 (2010-07-01), Chang et al.
patent: 2010/0221210 (2010-09-01), Chang et al.
patent: 2010/0233779 (2010-09-01), Govindan et al.
patent: 2010/0261885 (2010-10-01), Chang et al.
patent: 2011/0020273 (2011-01-01), Chang et al.
patent: 00/68248 (2000-11-01), None
patent: 2006/107617 (2006-10-01), None
patent: 2006/107786 (2006-10-01), None
patent: 2007/046893 (2007-04-01), None
patent: 2007/075270 (2007-07-01), None
Abbas et al., Cellular and Molecular Immunology, W.B. Saunders Comp. 1991, p. 43.
Alto et al., “Bioinformatic design of A-kinase anchoring protein-in silico: a potent and selective peptide antagonist of type II protein kinase A anchoring” Proc. Natl. Acad. Sci USA Apr. 15, 2003; 100(8):4445-50.
Backer et al., “Self-Assembled “Dock and Lock” System for Linking Payloads to Targeting Proteins” Bioconjugate Chem., 2006, 17(4):912-919.
Baillie et al., “Compartmentalisation of phospodiesterases and protein kinase A: opposites attract” FEBS Letters 2005; 579:3264-3270.
Banky et al., “Dimerization/Docking Domain of the Type Iα Regulatory Subunit of cAMP-dependent Protein Kinase” J. Biol. Chem. 273:35048-55, 1998.
Basu et al., “Structure-Function Engineering of Interferon-β-1b for Improving Stability, Solubility, Potency, Immunogenicity, and Pharmacokinetic Properties by Site-Selective Mono-PEGylation” Bioconjugate Chem. 2006; 17:618-630.
Belardelli et al., “Interferon-alpha in tumor immunity and immunotherapy” Cytokine Growth Factor Rev. 13(2):119-134 (2002).
Belardelli et al., “International Meeting on Cancer Vaccines: How Can We Enhance Efficacy of Therapeutic Vaccines?” Cancer Res. 64:6827-6830 (2004).
Belardelli et al., “The neglected role of type I interferon in the T-cell response: implications for its clinical use” Immunol. Today 17(8):369-72 (1996).
Biron et al., “Natural killer cells in antiviral defense: function and regulation by innate cytokines” Annu. Rev. Immunol. 17:189-220 (1999).
Brunda et al., “Modulation of Murine Natural Killer Cell Activity in Vitro and in Vivo by Recombinant Human Interferons” Cancer Res. 44:597-601 (1984).
Burns-Hamuro et al., “Distinct interaction modes of an AKAP bound to two regulatory subunit isoforms of protein kinase A revealed by amide hydrogen/deuterium exchange” Protein Science (2005), 14:2982-2992.
Carr et al., “Interaction of the Regulatory Subunit (RII) of cAMP-dependent Protein Kinase with RII-anchoring Proteins Occurs through an Amphipathic Helix Binding Motif” J. Biol. Chem. 266:14188-92 (1991).
Carr et al., “Identification of Sperm-specific Proteins That Interact with A-kinase Anchoring Proteins in a Manner Similar to the Type II Regulatory Subunit of PKA” J. Biol. Chem. 276(20):17332-17338 (2001).
Carrero et al., “Lymphocytes are detrimental during the early innate immune response against Listeria monocytogenes” J. Exp. Med. 203(4):933-940 (2006).
Chang et al., “The Dock and Lock Method: A Novel Platform Technology for Building Multivalent, Multifunctional Structures of Defined Composition with Retained Bioactivity” Clin. Cancer Res. Sep. 15, 2007;13(18 Suppl), pp. 5586-5591.
Chmura et al., “Antibodies with infinite affinity” Proc. Natl. Acad. Sci. USA 98(15):8480-8484 (2001).
Colledge et al., “AKAPs: from structure to function” Trends Cell Biol. 6:216-21 (1999).
Corbin et al., “Regulation of Adenosine 3′,5′-Monophosphate-dependent Protein Kinase” J. Biol. Chem. 248:1813-21 (1973).
Dhalluin et al., “Structural and Biophysical Characterization of the 40 kDa PEG-Interferon-α2a and Its Individual Positional Isomers” Bioconjugate Chem. 2005;16:504-517.
Dodart et al., “Immunotherapy for Alzheimer's Disease: will vaccination work?” Trends Mol. Med. 9(3):85-87 (2003).
Doherty et al., “Site-Specific PEGylation of Engineered Cysteine Analogues of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor” Bioconjugate Chem. 2005;16:1291-1298.
Ferrantini et al., “IFN-α1 Gene Expression into a Metastatic Murine Adenocarcinoma (TS/A) Results in CD8+ T Cell-Mediated Tumor Rejection and Development of Antitumor Immunity” J. Immunol. 153:4604-15 (1994).
Ferrantini et al., “Interferon-α and cancer: Mechanisms of action and new perspectives of clinical use” Biochimie 89: 884-893 (2007).
Foser et al., “Improved biological and transcriptional activity of monopegylated interferon-α-2a isomers” The Pharmacogenomics J 3:312-319 (2003).
Gillies et al., “High-level expression of chimeric antibodies using adapted cDNA variable region cassettes” J. Immunol. Methods 125 (1989) 191-202.
Glennie et al., “Mechanisms of killing by anti-CD20 monoclonal antibodies” Mol. Immunol. 44:3823-3837 (2007).
Gold et al., “A Novel Bispecific, Trivalent Antibody Construct for Targeting Pancreatic Carcinoma”, Cancer Res. 68:4819-26, 2008.
Gold et al., “Molecular Basis of AKAP Specificity for PKA Regulatory Subunits” Mol. Cell Nov. 3, 2006;24(3):383-95.
Goldenberg et al., “Multifunctional Antibodies by the Dock-and-Lock Method for Improved Cancer Imaging and Therapy by Pretargeting” J. Nucl. Med. 49:158-63, 2008.
Goldenberg et al., “Properties and structure-function relationships of veltuzumab (hA2
Chang Chien-Hsing
Goldenberg David M.
McBride William J.
Rossi Edmund A.
Huynh Phuong
IBC Pharmaceuticals, Inc.
Nakashima Richard A.
LandOfFree
PEGylation by the dock and lock (DNL) technique does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with PEGylation by the dock and lock (DNL) technique, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and PEGylation by the dock and lock (DNL) technique will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2623717